Products for Research Use Only
RegisterLogin

Tepoditamab

CAT: 0804-HY-P99390-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99390-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research[1][2][3].
CAS Number
2044679-53-8
Product Name Alternative
MCLA 117
UNSPSC
12352203
Target
CD3; IFNAR; Interleukin Related; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tepoditamab.html
Purity
99
Solubility
10 mM in DMSO
Smiles
[Tepoditamab]
Molecular Weight
(144.787 kDa)
References & Citations
[1]Naval Daver, et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021 Jul;35 (7) :1843-1863.|[2]van Loo, P. F., et al., (2019) . MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert opinion on biological therapy, 19 (7), 721–733. |[3]Pieter Fokko Van Loo, et al., Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML, Blood, Volume 126, Issue 23, 2015.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1

Alternative Products

CatalogName
E40YR1508Tepoditamab
GTR18337896-01Tepoditamab Antibody
MBS1563987-01Research Grade Tepoditamab
E55B1234Tepoditamab (Reference antibody)
592244Tepoditamab (CD3E, CLEC12A)
KBI1770KRIBIOLISA™ Tepoditamab ELISA
C00334-01Tepoditamab (Anti-CLEC12A / CD371)
048034CLEC12A/CD371 (tepoditamab) discontinued
ABS-382-100ugTepoditamab Biosimilar, Research Grade
GTR18697704-01Tepoditamab Human Monoclonal Antibody

Popular Products